Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate

The fight for dominance in the weight loss market is just getting started.Investors interested in the pharmaceutical industry are currently excited about the anti-obesity market. Weight-loss therapies have become the industry's versions of rock stars, and none is more popular than Novo Nordisk's Wegovy.Other companies are looking to challenge the Denmark-based drugmaker. Its longtime rival in the diabetes market, Eli Lilly (LLY 0.75%), recently launched a competing anti-obesity medicine called tirzepatide, ...